Exclusive Summary

• - About 8.5 million people live with Parkinson’s globally and aging will keep demand rising; ER pramipexole has a stable and expanding prescription base.
• - Key ER formulation patents/exclusivities have largely expired, with broad generic entry since 2017–2021 across major markets.
• - US registration and FDA-cGMP manufacturing enable reliance/abridged approvals and efficient multi-region distribution.
• - Once-daily SR smooths plasma levels and improves adherence, suitable as early monotherapy (selected patients) and as add-on to levodopa.
• - Pricing 70–90% below brand supports competitiveness in both tenders and retail channels.